C-LM4PNeuroBio
T14 peptide, biomarker diagnostics, neurodegeneration therapeutics
modulatingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-LM4P
C-LM4PC-LM4PT14 peptide, biomarker diagnostics, neurodegeneration therapeutics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Neuro-Bio Ltd presents itself as a biotechnology company focused on neurodegenerative disorders, especially Alzheimer’s disease, and states that it is developing a novel treatment approach based on its view that Alzheimer’s has an identifiable underlying mechanism and a novel peptide increased in the Alzheimer’s brain that is relevant to the disease.
SourceNeuro-Bio presents neurodegenerative disorders, especially Alzheimer's disease, as a global medical crisis requiring new therapeutics and biomarkers. It states that the company was founded to pursue Professor Susan Greenfield's once-heretical idea, which it says was matured and validated through decades of persistent research and stands in challenge to prevailing academic and industry dogma.
SourceNeuro-Bio states that it is a biotechnology company focused on developing therapeutics and biomarkers for neurodegenerative disorders, and that it exists to address what it describes as a global medical crisis driven by conditions such as Alzheimer's disease, which it says is the most common cause of dementia and may account for 60–70% of diagnosed dementia cases.
SourceNeuro-Bio presented itself as pursuing a disruptive, alternative approach to neurodegenerative disease, especially Alzheimer's, rather than relying only on mainstream assumptions. The company's stated position was that acetylcholinesterase has a previously overlooked pathogenic role: when its C-terminus is cleaved, the resulting peptide is toxic to neurons, and this mechanism may help drive neurodegeneration. Neuro-Bio also indicated that this mechanism could be therapeutically targeted with a cyclic peptide analogue intended to block neuronal death.
SourceNeuro-Bio states that neurodegenerative diseases, especially Alzheimer's disease, represent a major and growing global health crisis that has not been adequately addressed by existing drug development. The company says it has identified a mechanism that initiates the cycle of brain cell death underlying these conditions, and it believes that targeting the vulnerable, selective population of brain cells that first show signs of neurodegeneration can halt disease progression through novel therapeutics and biomarkers.
SourceNeuro-Bio states that it is developing a paradigm-shifting therapeutic approach for neurodegenerative disorders such as Alzheimer's, Parkinson's, and Motor Neuron Disease. The company says it was first to identify a novel mechanism driving the cycle of brain cell death in selectively vulnerable cell groups, argues that beta-amyloid and tau production are secondary phenomena rather than primary causes, and claims this mechanism can be targeted with novel drug candidates that could halt neurodegeneration. It also states that the same mechanism may operate in metastatic cancers, suggesting possible oncology applications.
Source